Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

hegdaom Mar. 18 at 11:25 PM

$CAPR

0 · Reply

ODLH Mar. 18 at 10:29 PM

$CAPR Why does fintel show only 48% institution ownership now? I don’t see any big holders reduce positions except Highbridge.

1 · Reply

Stonksgoingup Mar. 18 at 10:14 PM

$CAPR feels like we finally became a recession free stock

0 · Reply

bond1971 Mar. 18 at 10:03 PM

$CAPR the future is STRONG

0 · Reply

ProfitPills Mar. 18 at 8:31 PM

$VALE $CAPR $DGXX $HIMX news

0 · Reply

BanditQ Mar. 18 at 8:12 PM

$ABVX $CAPR $EQ haven't sold a single share 💀

2 · Reply

MetalFistSlip Mar. 18 at 8:11 PM

$CAPR $ONDS $SLS Lion0fWallSt trying to make it back to $0.00 after having his margin account liquidated from SLS and CAPR… Moving on…

0 · Reply

Lion0fWallSt Mar. 18 at 7:58 PM

$CAPR $ONDS $SLS When Poppy started taking margin to short the signal was to sell.

1 · Reply

Dash_Man Mar. 18 at 7:40 PM

$CAPR https://musculardystrophynews.com/news/mda-2026-fda-decision-deramiocel-dmd-expected-2026/

0 · Reply

Parsnip Mar. 18 at 7:35 PM

$CAPR The Creature from Jekyll Island strikes again !

0 · Reply

Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel

Mar 13, 2026, 1:27 PM EDT - 5 days ago

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Mar 12, 2026, 8:02 PM EDT - 6 days ago

Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript

Mar 12, 2026, 4:01 PM EDT - 6 days ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 9:00 AM EDT - 6 days ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Mar 10, 2026, 10:47 AM EDT - 8 days ago

Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Mar 10, 2026, 9:25 AM EDT - 8 days ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Mar 9, 2026, 1:32 PM EDT - 9 days ago

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

MRNA

Dec 17, 2025, 7:59 PM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 3 months ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 3 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 3 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 3 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 3 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 4 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 4 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 4 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 4 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 5 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 6 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 6 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 6 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 6 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 6 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 7 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 8 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

hegdaom Mar. 18 at 11:25 PM

$CAPR

0 · Reply

ODLH Mar. 18 at 10:29 PM

$CAPR Why does fintel show only 48% institution ownership now? I don’t see any big holders reduce positions except Highbridge.

1 · Reply

Stonksgoingup Mar. 18 at 10:14 PM

$CAPR feels like we finally became a recession free stock

0 · Reply

bond1971 Mar. 18 at 10:03 PM

$CAPR the future is STRONG

0 · Reply

ProfitPills Mar. 18 at 8:31 PM

$VALE $CAPR $DGXX $HIMX news

0 · Reply

BanditQ Mar. 18 at 8:12 PM

$ABVX $CAPR $EQ haven't sold a single share 💀

2 · Reply

MetalFistSlip Mar. 18 at 8:11 PM

$CAPR $ONDS $SLS Lion0fWallSt trying to make it back to $0.00 after having his margin account liquidated from SLS and CAPR… Moving on…

0 · Reply

Lion0fWallSt Mar. 18 at 7:58 PM

$CAPR $ONDS $SLS When Poppy started taking margin to short the signal was to sell.

1 · Reply

Dash_Man Mar. 18 at 7:40 PM

$CAPR https://musculardystrophynews.com/news/mda-2026-fda-decision-deramiocel-dmd-expected-2026/

0 · Reply

Parsnip Mar. 18 at 7:35 PM

$CAPR The Creature from Jekyll Island strikes again !

0 · Reply

patatechaude Mar. 18 at 7:27 PM

$CAPR I have dry powder left and will add.

1 · Reply

wkee Mar. 18 at 7:20 PM

$CAPR I not selling !! Capr science for the win!! Linda 🏆

1 · Reply

dnfrs Mar. 18 at 6:46 PM

$CAPR In a market worried about inflation and interest rates, I am glad I found an investment that is cash rich, and getting richer! Several partnerships and nice upfronts and milestones are on the way! Capricor has two world class technologies ready to meet many milestones this year and next. * Deramiocel will enter the market and become the leading technology to fight cardiomyopathy. * StealthX will enter the clinic with several ( 3 or more) Therapeutics based on exosome drug delivery. I don't know a safer and more dynamic place to invest for the next few years! Due your own DD. It is worth a look IMO!

1 · Reply

Elon_Trumpet Mar. 18 at 6:43 PM

$CAPR no one is selling. Strong hands here finally

0 · Reply

buckiii2 Mar. 18 at 6:19 PM

$CAPR What did you vote for? Our homeland to get hit by Iran?

2 · Reply

Wallstreetiscriminal Mar. 18 at 6:05 PM

$CAPR Well the good news is you can tell the word is getting out by the number of new Reddit penny flippers showing up recently. Buy buy buy! To the moon! Wen lambo?

0 · Reply

Dash_Man Mar. 18 at 5:55 PM

$CAPR https://x.com/cingolani_oscar/status/2034258142519833047

0 · Reply

Patches62 Mar. 18 at 5:41 PM

$CAPR .....okay.....whoever brought this HeapofFunk guy here......you can take him home now....joke

1 · Reply

patatechaude Mar. 18 at 5:07 PM

$CAPR We would be at +$40 if it wasn’t from the White House induced chaos. I’m getting tired of the mess we’re in. This is not what I voted for. Anyway, FDA approval is a done deal and we might see $100 this year folks.

7 · Reply

clarksonhockey Mar. 18 at 4:54 PM

$CAPR acting well... buy on weakness non stop till summer...stay thirsty..

0 · Reply

Notquiteabillionaire Mar. 18 at 4:54 PM

$CAPR likely the algo's are also getting bored with this daily SP game. On the bright side, $30 seems to be being respected by the Game Masters🧙‍♂️🧌 😎

0 · Reply

Stockgod26 Mar. 18 at 4:53 PM

$IBRX can’t stop won’t stop $CAPR men and women have seen this game for years….no sell

2 · Reply

Market Cap	1.69B
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	49.08
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	950,600
Avg Vol	1,355,880
Day's Range	N/A - N/A
Shares Out	55.31M
Stochastic %K	48%
Beta	0.37
Analysts	Strong Sell
Price Target	$53.40